aldesleukin + sargramostim + vinblastine sulfate

A three-drug investigational combination comprising the cytokines **aldesleukin** (recombinant interleukin‑2), **sargramostim** (recombinant granulocyte‑macrophage colony-stimulating factor), and the vinca alkaloid **vinblastine sulfate**. Aldesleukin stimulates proliferation and activation of T cells and NK cells and induces cytokine production, mediating antitumor immune responses; it is approved as monotherapy for metastatic melanoma and metastatic renal cell carcinoma[5][9][1]. Vinblastine sulfate is a microtubule inhibitor chemotherapeutic that blocks mitosis by interfering with microtubule polymerization, classified as a vinca alkaloid and used across multiple cancers[2][4][8]. Sargramostim is a recombinant GM‑CSF used to stimulate granulocyte and macrophage production and function; in oncology, it is often used to enhance immune responses and support myeloid recovery (inference based on established GM‑CSF pharmacology; no specific label for this three-drug combo identified). Together, this regimen represents an immunochemotherapy approach combining cytokine-driven immune activation with cytotoxic antimitotic activity.